Page 96 - 《中国药房》2023年18期

in patients with muscle-invasive bladder cancer[J]. J Clin approach to muscle-invasive urothelial bladder cancer
Oncol，2021，39（28）：3140-3148. （MIBC） patients（pts） prospectively selected by an inter‐
[22] FUNT S A，LATTANZI M，WHITING K，et al. Neoadju‐ feron（INF）-gamma immune signature[J]. J Clin Oncol，
vant atezolizumab with gemcitabine and cisplatin in 2020，38（15_suppl）：5012.
patients with muscle-invasive bladder cancer：a multi‐ [32] THIBAULT C，ELAIDI R，VANO Y A，et al. Open-label
center，single-arm，phase Ⅱ trial[J]. J Clin Oncol，2022， phase Ⅱ to evaluate the efficacy of neoadjuvant dose-
40（12）：1312-1322. dense MVAC in combination with durvalumab and treme‐
[23] ZHANG R Y，ZANG J Y，XIE F，et al. Longitudinal limumab in muscle-invasive urothelial carcinoma：NEMIO
personalized urinary tumor DNA analysis in muscle- [J]. Bull Cancer，2020，107（5S）：eS8-eS15.
invasive bladder cancer from the neoadjuvant immuno‐ [33] LIN T X，LI K W，FAN J H，et al. Interim results from a
therapy trial RJBLC-I2N003[J]. J Clin Oncol，2022，40 multicenter clinical study of tislelizumab combined with
（6_suppl）：552. gemcitabine and cisplatin as neoadjuvant therapy for
[24] NATESAN D V，ZHANG L，OH D Y，et al. Updated patients with cT2-T4aN0M0 MIBC[J]. J Clin Oncol，
results of phase Ⅱ trial using escalating doses of neoadju‐ 2022，40（16_suppl）：4580.
vant atezolizumab for cisplatin-ineligible patients with [34] VAN DORP J，SUELMANN B B M，MEHRA N，et al.
nonmetastatic urothelial cancer（NCT02451423）[J]. J Clin LBA31 High- vs low-dose pre-operative ipilimumab and
Oncol，2021，39（15_suppl）：e16510. nivolumab in locoregionally advanced urothelial cancer
[25] WEI X X，ALEXANDER MCGREGOR B，LEE R J，et （NABUCCO cohort 2）[J]. Ann Oncol，2021，32：S1305-
al. Durvalumab as neoadjuvant therapy for muscle-invasive S1306.
bladder cancer：preliminary results from the Bladder Cancer [35] NECCHI A，MARTINI A，RAGGI D，et al. A feasibility
Signal Seeking Trial（BLASST）-2[J]. J Clin Oncol，2020， study of preoperative pembrolizumab before radical
38（6_suppl）：507. nephroureterectomy in patients with high-risk，upper tract
[26] GOUBET A G，ALVES COSTA SILVA C，LORDELLO urothelial carcinoma：pure-02[J]. Urol Oncol，2022，40
DE MELO L，et al. Bacteria-specific CXCL13-producing （1）：10.e1-10.e6.
follicular helper T cells are putative prognostic markers to [36] KAIMAKLIOTIS H Z，ADRA N，KELLY W K，et al.
neoadjuvant PD-1 blockade in muscle-invasive urothelial Phase Ⅱ neoadjuvant（N-） gemcitabine（G） and pembroli‐
carcinoma[J]. J Clin Oncol，2022，40（6_suppl）：535. zumab （P） for locally advanced urothelial cancer
[27] GUERCIO B J，PIETZAK E J，BROWN S，et al. Neoadju‐ （LAUC）：interim results from the cisplatin（C）-ineligible
vant nivolumab （N） +/- ipilimumab （I） in cisplatin- cohort of GU14-188[J]. J Clin Oncol，2020，38（15_
ineligible patients（pts）with muscle-invasive bladder can‐ suppl）：5019.
cer（MIBC）[J]. J Clin Oncol，2022，40（6_suppl）：498. [37] LOWE M C，KUDCHADKAR R R. Neoadjuvant therapy
[28] GRIVAS P，YIN J，KOSHKIN V S，et al. PrE0807：A for melanoma[J]. Surg Oncol Clin N Am，2020，29（3）：
phase Ⅰb feasibility trial of neoadjuvant nivolumab（N） 445-53.
without or with lirilumab（L） in cisplatin-ineligible [38] YIN Z，YU M，MA T T，et al. Mechanisms underlying
patients（pts）with muscle-invasive bladder cancer（MIBC） low-clinical responses to PD-1/PD-L1 blocking antibodies
[J]. J Clin Oncol，2021，39（15_suppl）：4518. in immunotherapy of cancer：a key role of exosomal
[29] KIM H，KIM R，HONG J，et al. A prospective phase Ⅱ PD-L1[J]. J Immunother Cancer，2021，9（1）：e001698.
trial of neoadjuvant nivolumab plus gemcitabine/cisplatin [39] YI M，ZHENG X，NIU M，et al. Combination strategies
chemotherapy in muscle-invasive urothelial carcinoma of with PD-1/PD-L1 blockade：current advances and future
bladder[J]. J Clin Oncol，2022，40（6_suppl）：494. directions [J]. Mol Cancer，2022，21（1）：28.
[30] XING N，HAN S，JIANG J，et al. 703P Camrelizumab in [40] BOUTROS C，TARHINI A，ROUTIER E，et al. Safety
combination with gemcitabine plus cisplatin as neoadju‐ profiles of anti-CTLA-4 and anti-PD-1 antibodies alone
vant therapy for muscle-invasive bladder cancer[J]. Ann and in combination[J]. Nat Rev Clin Oncol，2016，13（8）：
Oncol，2021，32：S714. 473-486.
[31] GRANDE E，GUERRERO F，PUENTE J，et al. Dutreneo （收稿日期：2023-02-08 修回日期：2023-08-06）
trial：a randomized phase Ⅱ trial of durvalumab and （编辑：陈 宏）
tremelimumab versus chemotherapy as a neoadjuvant

· 2262 · China Pharmacy 2023 Vol. 34 No. 18 中国药房 2023年第34卷第18期